LUDWIG ENTERPRISES, INC.

S-1/A amended

Ludwig Enterprises, Inc. is conducting a firm commitment public offering of 1,670,379 common units, each consisting of one share of common stock and one warrant, at an assumed offering price of $8.98 per unit. The offering includes a 1-for-200 reverse stock split, pending FINRA approval, to qualify for listing on a specified exchange. The company aims to transition from the OTCID to a more liquid market, though risks include regulatory approvals, limited trading history, and high investment risk.

S-1/A amended

Ludwig Enterprises, Inc. is conducting a firm commitment public offering of 3,750,002 Common Units, each consisting of one share of common stock and one warrant. The offering includes a proposed 100:1 reverse stock split to facilitate listing on a specified exchange. The company aims to develop genomics-based tests for chronic inflammatory diseases, with its initial product, the Revealia™ Breast test, pending commercial launch. The filing highlights risks related to regulatory approvals, market acceptance, and the company's early-stage operations.

S-1/A amended

Ludwig Enterprises, Inc. is conducting a firm commitment public offering of its common stock, with an assumed public offering price of $0.001 per share. The company plans to effect a reverse stock split (1-for-50 to 1-for-250) to qualify for uplisting, though the exact ratio remains undetermined. Convertible preferred stock and notes will convert into common stock, with proceeds partially used to settle outstanding convertible note balances. The offering faces risks related to reverse split approval, limited public market liquidity, and reliance on a single product (Revealia TM Breast test).

S-1 filed

Ludwig Enterprises, Inc. is conducting an IPO involving the issuance of common stock, with plans to effect a reverse stock split to qualify for listing on a specified exchange. The offering includes conversion of convertible preferred stock and notes into common shares, and the company intends to use proceeds to settle outstanding convertible note balances. The company is an emerging growth company with limited public trading history and faces risks related to regulatory approvals and market adoption.

8-A12B effective

Ludwig Enterprises, Inc. filed an 8-A12B form to register its common stock under Section 12(g) of the Securities Exchange Act of 1934. The filing incorporates by reference the description of securities from its previously effective S-1 registration statement (File No. 333-271439), which was initially filed in April 2023 and last amended in November 2023. The current filing focuses on registering shares of common stock with a $0.001 par value, without including a prospectus or offering details.

EFFECT effective

Ludwig Enterprises, Inc. has filed a registration statement (Form S-1) for the offering of 47,000,000 shares of common stock at an estimated price range of $0.30-0.60 per share. The offering is self-underwritten by the company's president, with proceeds not escrowed. Convertible notes totaling $1,040,000 may convert into shares at 80% of the offering price. The company is an emerging growth company with reduced reporting requirements, and the offering involves significant risks, including limited market liquidity and control by convertible preferred stockholders.

S-1/A amended

Ludwig Enterprises, Inc. is conducting an IPO to raise capital through the sale of 47,000,000 shares of common stock at an offering price of $0.30-0.60 per share. The company aims to leverage its proprietary mRNA genetic testing kits and anti-inflammatory supplements to target the genomics and wellness markets. The offering includes convertible notes eligible for conversion into common stock, with significant risks outlined related to market volatility, control by preferred stockholders, and limited operating history.

S-1/A amended

Ludwig Enterprises, Inc. is offering 47,000,000 shares of common stock in a self-underwritten, best-efforts offering. The company aims to commercialize mRNA genetic testing kits and anti-inflammatory supplements, with plans to launch products in Q4 2023. The offering includes convertible notes convertible into common stock at 80% of the offering price. The company is an emerging growth company with limited operating history and significant risks, including lack of active trading market and control by convertible preferred stockholders.

S-1/A amended

Ludwig Enterprises, Inc. is offering 47,000,000 shares of common stock at an estimated price range of $0.75-$1.25 per share. The company develops mRNA genetic testing kits and anti-inflammatory supplements, targeting inflammatory disease detection and management. The offering includes convertible notes convertible into common stock at 80% of the offering price. The company has a history of losses, limited market liquidity, and no established sales or manufacturing infrastructure. The offering is highly speculative with significant risks, including control by convertible preferred stockholders and lack of FDA approval for supplements.

S-1/A amended

Ludwig Enterprises, Inc. is conducting an IPO to raise capital through the sale of 47,000,000 shares of common stock at an estimated price range of $0.75-$1.25 per share. The company develops mRNA genetic testing kits and anti-inflammatory supplements targeting inflammatory disease markers. The offering includes convertible notes convertible into common stock at 80% of the offering price. The company faces risks related to its history of losses, limited market liquidity, and control by convertible preferred stockholders. The offering is highly speculative, with no guaranteed market for its securities.

S-1/A amended

Ludwig Enterprises, Inc. is offering 47,000,000 shares of common stock at an estimated price range of $0.75-$1.25 per share. The company develops mRNA genetic testing kits and anti-inflammatory nutritional supplements, targeting the wellness and healthcare markets. The offering includes convertible notes that may convert into shares at 80% of the offering price. The company is an emerging growth company with limited operating history, facing risks related to market adoption, regulatory compliance, and dependence on a single product line.

S-1/A amended

Ludwig Enterprises, Inc. is offering 47,000,000 shares of common stock in a self-underwritten, best-efforts offering. The company develops mRNA genetic testing kits and anti-inflammatory nutritional supplements targeting inflammatory disease detection and management. The offering includes convertible notes convertible into common stock at 80% of the offering price. The company anticipates launching its supplement in Q3 2023 and its home test kit in Q4 2023, with risks including limited market demand, control by convertible preferred stockholders, and history of losses.

S-1/A amended

Ludwig Enterprises, Inc. is offering 47,000,000 shares of common stock at an anticipated price range of $0.75-$1.25 per share. The company develops mRNA genetic testing kits and anti-inflammatory nutritional supplements, targeting inflammation-related disease detection and monitoring. The offering includes convertible notes convertible into shares at 80% of the offering price. The company is an emerging growth company with limited operating history, no FDA-approved products, and significant risks related to market acceptance, competition, and capital requirements.

S-1 filed

Ludwig Enterprises, Inc. is offering 47,000,000 shares of common stock via an S-1 registration, aiming to raise capital for its mRNA genetic testing kits and anti-inflammatory supplements. The company focuses on detecting inflammatory genetic markers for diseases like heart disease and cancer, with plans to launch products in Q3 2023. The offering includes convertible notes convertible into shares at 80% of the offering price. The company operates in a competitive market with risks including limited commercialization experience, reliance on a single product, and uncertainty around market adoption.

DRS filed

Ludwig Enterprises, Inc. is conducting an IPO to raise capital through the sale of 47,000,000 shares of common stock at an estimated price range of $0.75-$1.25 per share. The company, a genomics technology firm, focuses on developing mRNA-based diagnostic tools and supplements for inflammatory diseases. The offering includes conversion rights for existing convertible notes into common stock. The company's stock is currently quoted on the OTC Pink market, but there is no guarantee of an active trading market. The offering is highly speculative, with significant risks including lack of revenue, dependence on key personnel, and regulatory uncertainties.